Skip to main content

Journal of the International AIDS Society

Ausgabe Sonderheft 4/2010

Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection

Inhalt (290 Artikel)

Open Access Keynote presentation

ART achievements and challenges in Africa

J Hakim

Open Access Oral presentation

O114. Long-term probability of detecting drug-resistant HIV in patients starting antiretroviral therapy within the first year of HIV infection

S Lodi, C Kücherer, AM Bakken Kran, B Masquelier, A d'Arminio Monforte, J Gill, D Dunn, D Pillay, K Porter

Open Access Oral presentation

O115. Low-level residual viremia and risk of virological failure

G Cologni, L Soavi, S Leone, D Valenti, A Callegaro, G Gregis, F Suter, F Maggiolo

Open Access Oral presentation

O116. The EuResist expert model for customised HAART optimisation: 2010 update and extension to newest compounds

A Pironti, A Sönnerborg, M Zazzi, R Kaiser, D Struck, B Clotet, ÀM Vandamme, F Incardona, T Lengauer, M Rosen-Zvi, M Prosperi

Open Access Oral presentation

O121. Consensus statement of the European guidelines on clinical management of HIV-1 tropism testing

LPR Vandekerckhove, AMJ Wensing, R Kaiser, F Brun-Vezinet, B Clotet, A De Luca, S Dressler, F Garcia, AM Geretti, T Klimkait, K Korn, B Masquelier, CF Perno, J Schapiro, V Soriano, A Sönnerborg, ÀM Vandamme, C Verhofstede, H Walter, M Zazzi, CA Boucher

Open Access Oral presentation

O123. Short-term variation of HIV tropism readouts in the absence of CCR5 antagonists

CJ Brumme, W Dong, D Chan, T Mo, LC Swenson, C Woods, J Demarest, J Heera, H Valdez, PR Harrigan

Open Access Oral presentation

O124. Impact of baseline HIV-1 tropism on viral response and CD4 gains in antiretroviral-naïve patients

E Seclén, M Gonzalez, L Martín-Carbonero, H Gellermann, V Cairns, M Distel, W Kadus, V Soriano, E Poveda

Open Access Oral presentation

O125. Influence of amount and percentage of CXCR4-using virus in predicting week 48 responses to maraviroc in treatment-naïve patients

H Valdez, D Chapman, P Biswai, M Lewis, C Craig, J Heera, S Ellery, LC Swenson, PR Harrigan

Open Access Oral presentation

O132. Treatment-as-prevention: stopping the epidemic of HIV

B Williams

Open Access Oral presentation

O133. Test and treat — community perspectives

B Spire

Open Access Oral presentation

O134. HIV treatment as prevention — human rights issues

J Amon

Open Access Oral presentation

O135. A pilot study to determine the prevalence of HIV in persons presenting for care with selected conditions: preliminary results from the HIV in Europe study

A Sönnerborg, A Mocroft, JD Lundgren, D Raben, J Gatell, A Vassilenko, V Hadziosmanovic, J Bergovac, H Sørensen, M Cusini, N Clumeck, B Gazzard, J Rockstroh, M Zuin, A D'Arminio Monforte

Open Access Oral presentation

O211. The state of PI monotherapy and NRTI-sparing therapy

JR Arribas

Open Access Oral presentation

O212. Ritonavir-boosted protease inhibitor monotherapy is 6% less effective than combination antiretroviral therapy in a meta-analysis

WFW Bierman, EH Humphreys, MA van Agtmael, CA Boucher, GW Rutherford

Open Access Oral presentation

O213. Low-level viraemia during treatment with darunavir/r monotherapy versus DRV/r + 2NRTIs in the MONET trial

N Clumeck, JR Arribas, P Pulick, G Fätkenheuer, A Hill, Y Van Delft, C Moecklinghoff

Open Access Oral presentation

O214. Virological findings from the SARA trial: boosted PI monotherapy as maintenance second-line ART in Africa

D Pillay, R Goodall, CF Gilks, D Yirrell, D Gibb, M Spyer, P Kaleebu, P Munderi, C Kityo, A McCormick, J Nkalubo, F Lyagoba, M Chirara, J Hakim

Open Access Oral presentation

0215. Virological outcomes in ARV-naïve patients switching or not from a first successful boosted PI-regimen to efavirenz, nevirapine or abacavir regimens

T Bommenel, JL Meynard, O Launay, A Simon, A Mahamat, V Martinez, J Gilquin, C Katlama, AS Lascaux, C Pradier, E Rouveix, D Costagliola, S Abgrall

Open Access Oral presentation

0221. The clinical development of NRTIs — cautionary tales

D Cooper

Open Access Oral presentation

0223. Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children

C Zhang, P Denti, USH Simonsson, G Maartens, MO Karlsson, H McIlleron

Open Access Oral presentation

0231. Growing old with HIV — dealing with co-morbidities

W Powderly

Open Access Oral presentation

0234. Mitochondrial ageing and antiretroviral therapy exposure

BAI Payne, CA Hateley, DC Samuels, IJ Wilson, M Santibanez-Koref, DA Price, PF Chinnery

Open Access Oral presentation

0311. Hepatitis C new drugs

H Wedemeyer

Open Access Oral presentation

0312. Host genetics of HCV disease — IL28B

J Fellay

Open Access Oral presentation

0314. Efficacy and safety of peginterferon alfa-2a + RBV in cHCV/HIV- vs cHCV-infected patients: interim analysis of a multicenter German cohort

A Baumgarten, T Lutz, P Kreckel, E Wellmann, U Alshuth, S Mauss, J Rockstroh

Open Access Oral presentation

0315. The pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers

J Ashby, LJ Garvey, OW Erlwein, H Lamba, R Weston, K Legg, MO McClure, L Dickinson, A D'Avolio, DJ Back, A Winston

Open Access Oral presentation

How early to start: what do observational data suggest?

J Sterne

Open Access Oral presentation

HIV/HAART and the brain — what's going on?

P Portegies

Open Access Oral presentation

Adolescents with perinatally acquired HIV — coming your way

C Foster

Open Access Oral presentation

Early mortality following ART initiation in HIV-infected adults and children in Uganda and Zimbabwe

AS Walker, P Mugyenyi, P Munderi, J Hakim, AA Kekitiinwa, E Katabira, CF Gilks, C Kityo, P Nahirya-Ntege, K Nathoo, D Gibb

Open Access Oral presentation

Fatal and non-fatal AIDS and non-AIDS events in HIV-1 infected patients with high CD4 counts

J Reekie, J Gatell, I Yust, E Bakowska, A Rachmanova, M Losso, M Krasnov, P Francioli, J Kowalska, A Mocroft

Open Access Oral presentation

Cardiovascular risk assessment in persons with HIV in the developing world: comparing three risk equations in a cohort of HIV-infected Thais

N Edwards-Jackson, SJ Kerr, HV Tieu, J Ananworanich, SM Hammer, K Ruxrungtham, P Phanuphak, A Avihingsanon

Open Access Oral presentation

What affects the bone in our HIV-positive patients?

CA Fux

Open Access Oral presentation

Vitamin D and HIV: shine a light

J Currier

Open Access Oral presentation

Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study

JP Viard, JC Souberbielle, O Kirk, B Knysz, M Losso, J Gatell, C Pedersen, JR Bogner, A Mocroft, JD Lundgren

Open Access Oral presentation

Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART

S Rusconi, P Vitiello, F Adorni, E Colella, E Focà, AF Capetti, P Meraviglia, C Abeli, S Bonora, M D'Annunzio, A Di Biagio, A Di Pietro, L Butini, G Orofino, S Farina, G d'Ettorre, D Francisci, A Soria, AR Buonomini, C Tommasi, MP Trotta, M Capasso, E Merlini, GC Marchetti

Open Access Oral presentation

Maraviroc (MVC) increases CD4+ and CD8+ cells: long-term data from the MVC clinical development program

A Lazzarin, JG Sierra-Madero, M Battegay, G Mukwaya, R Burnside, D Chapman, J McCracken, S Portsmouth, S Valluri, H Valdez, J Heera

Open Access Oral presentation

HIV entry blocked by maraviroc can cause an overestimation of viral load

RD Sloan, BD Kuhl, VG Kramer, DA Donahue, T Bar-Magen, R Tressler, MA Wainberg

Open Access Oral presentation

The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients

HJ Stellbrink, S Rugina, C Zagler, S Esser, A Castagna, B Gazzard, A Hill, Y van Delft, S Marks

Open Access Oral presentation

Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patients

C Cohen, JM Molina, P Cahn, B Clotet, J Fourie, B Grinsztejn, W Hao, M Johnson, K Supparatpinyo, HM Crauwels, L Rimsky, S Vanveggel, P Williams, K Boven

Open Access Oral presentation

Lersivirine: a new NNRTI active across HIV-1 subtypes with a unique resistance profile

J Mori, M Westby, M Tawadrous, E van der Ryst, C Charles

Open Access Oral presentation

Once-daily S/GSK1349572 combination therapy in antiretroviral-naïve adults: rapid and potent 24-week antiviral responses in SPRING-1 (ING112276)

J Rockstroh, F Felizarta, F Maggiolo, F Pulido, HJ Stellbrink, O Tsybakova, P Yeni, S Almond, C Brothers, I Song, S Min

Open Access Oral presentation

Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)

J Eron, JM Livrozet, P Morlat, A Lazzarin, C Katlama, T Hawkins, T Fujiwara, R Cuffe, C Vavro, J Santiago, M Ait-Khaled, S Min, JM Yeo

Open Access Poster presentation

Health-related quality of life and fatigue in HIV-1 infected patients diagnosed during primary versus chronic infection

R Steingrover, MAF Nievaard, JMA Lange, PT Nieuwkerk, JM Prins

Open Access Poster presentation

The management of acute retroviral syndrome

A Hristea, R Petre, S Gliga, I Olaru, M Ion, R Moroti, C Popescu, R Mihailescu, M Radulescu, V Arama

Open Access Poster presentation

ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults

C Orkin, E DeJesus, H Khanlou, A Stoehr, K Supparatpinyo, T Van de Casteele, E Lathouwers, S Spinosa-Guzman

Open Access Poster presentation

Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir

S Nozza, L Galli, M Di Pietro, F Mazzotta, F Canducci, M Pogliaghi, S Chiappetta, A Galli, V Rusconi, S Salpietro, G Tambussi, A Lazzarin

Open Access Poster presentation

5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)

A Lazzarin, M Johnson, E Ribera, L Weitner, SS Chen, DR Warren

Open Access Poster presentation

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients

P Kumar, E DeJesus, G Huhn, L Sloan, F Garcia, C Small, H Edelstein, F Felizarta, R Hao, B Ha, B Stancil, L Ross, K Oie, K Pappa

Open Access Poster presentation

Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug

E Billaud, JM Lacombe, A Abgrall, J Ghosn, O Launay, JM Livrozet, JL Meynard, J Pavie, D Costagliola

Open Access Poster presentation

Comparative efficacy and safety of regimens including ritonavir-boosted lopinavir or nevirapine in antiretroviral-naïve HIV-1-infected individuals

A Pereira, JP Lopes da Cruz, C Carvalho, C Gonçalves, F Antunes

Open Access Poster presentation

Efficacy and safety of TDF/FTC-containing, first-line HAART in clinical practice: 3-year data from the German outpatient cohort

J van Lunzen, G Fätkenheuer, T Lutz, S Klauke, S Mauss, H Knechten, P Braun, L Gallo, J Goldbach

Open Access Poster presentation

Reasons for treatment discontinuation in the first year after beginning antiretroviral therapy in a cohort of Portuguese HIV-infected patients

C Caldas, P Andrade, C Azevedo, C Piñeiro, R Serrão, J Soares, R Marques, A Sarmento

Open Access Poster presentation

Insights into antiretroviral treatment changes in previously naïve patients: results of a Portuguese cohort

C Silva, D Bento, J Rijo, D Alfaiate, I Aldir, C Araújo, H Farinha, K Mansinho

Open Access Poster presentation

Factors associated with treatment modification during the first year of contemporary HAART

N Martin, I Perez-Valero, B San Jose Valiente, M Mora, JI Bernardino-Serna, J Gonzalez, F Gaya, FX Zamora, JM Pena, JR Arribas

Open Access Poster presentation

Impact of timing HAART initiation on immune status and clinical course in the cohort of the German competence network for HIV/AIDS

A Plettenberg, NH Brockmeyer, B Haastert, S Dupke, CK Schewe, M Rausch, M Hower, G Arendt, K Jansen, HIV KompNet

Open Access Poster presentation

Efficient immune reconstitution in HIV+ naïve patients (pts) starting a first lopinavir/ritonavir-containing regimen with low CD4 counts

E Merlini, E Sinigaglia, G Carpani, T Bini, A d'Arminio Monforte, GC Marchetti

Open Access Poster presentation

Immunological response among patients with undetectable viral load followed for 5 years

C Piñeiro, AS Santos, S Cardoso, J Nuak, R Lucas, A Ferreira, S Xerinda, M Tavares, R Marques, A Sarmento

Open Access Poster presentation

Sex matters: retrospective data collection on the date of commencement of ART for HIV-positive women and men in the German KompNet cohort (1991-2009)

I Krznaric, A Wienbreyer, A Zoufaly, P Kreckel, S Esser, T Harrer, K Jansen, C Michalik, S Hertling

Open Access Poster presentation

Response to HAART according to sex and origin (immigrant vs autochthonous) in a cohort of patients who initiate antiretroviral treatment

JA Perez-Molina, M Mora-Rillo, I Suarez-Lozano, JL Casado, R Teira, P Rivas, E Pedrol, A Hernando, P Domingo, E Barquilla, H Esteban, J Gonzalez-Garcia

Open Access Poster presentation

Influence of demographic and disease parameters on virological response to once- vs twice-daily darunavir/ritonavir (DRV/r) at week 48 in ODIN

M Sension, C Arns Da Cunha, P Domingo, K Supparatpinyo, T Van De Casteele, P De Doncker, F Tomaka

Open Access Poster presentation

Health-related quality of life (HRQoL) assessment with once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial

S Spinosa-Guzman, T Van de Casteele, G De La Rosa, P De Doncker

Open Access Poster presentation

Darunavir in experienced patients

G Sterrantino, B Borchi, M Trotta, D Bartolozzi, F Leoncini

Open Access Poster presentation

Efficacy and tolerability of darunavir/r 600/100 mg bid in treatment-experienced patients: 48-week data from a German outpatient cohort

J van Lunzen, D Gorriahn, T Wünsche, S Dupke, P Gute, CK Schewe, B Ranneberg

Open Access Poster presentation

Week 48 efficacy of 900/100 mg daily of darunavir/ritonavir in treatment-experienced HIV-1 patients with virological success: DARDAR study

L Schneider, A Houssaini, S Lambert, G Peytavin, R Agher, A Chermak, P Flandre, V Calvez, AG Marcelin, J Ghosn, C Katlama

Open Access Poster presentation

Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1

L Maroldo, LM Fredrick, K Robinson-Morgan, R Trinh, TJ Podsadecki

Open Access Poster presentation

Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced HIV patients

K Jansen, A Sönnerborg, P Pugliese, S Biguenet, JL Eychenne, NH Brockmeyer, C Michalik, S Dupke, H Jaeger, A Plettenberg, D Butcher, MJ Jiménez-Expósito, HIV KompNet

Open Access Poster presentation

Integrase inhibitor-based treatment in clinical practice

G Cenderello, R Piscopo, M Feasi, G Penco, N Bobbio, G Cassola

Open Access Poster presentation

Switching to a 'nuke-sparing' raltegravir/atazanavir combination: an individualised approach

A Grant, Y Kamuntu, P Read, R Kulasegaram

Open Access Poster presentation

Portuguese cohort: raltegravir with optimized background therapy (OBT) in multiple-experienced HIV1- and HIV2-infected patients

M Doroana, C Piñeiro, F Maltez, P Fonseca, J Oliveira, K Mansinho, A Horta, E Teófilo, M Aguas, I Germano, D Faria

Open Access Poster presentation

Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice

JM Llibre, E Martínez, P Barreiro, R Escrig, E Ribera, M Cervantes, A Imaz, F Gutierrez, H Knobel, A Ornelas, FX Zamora, B Clotet

Open Access Poster presentation

Use of once-daily raltegravir-based HAART in HIV-infected injection drug users

HK Tossonian, JD Raffa, O Alenezi, K Anderson, S Jassemi, K Wight, S DeVlaming, B Conway

Open Access Poster presentation

Temporal trend of the first prescription of nevirapine: the ANRS CO3 Aquitaine Cohort, 1997-2008

M Bruyand, S Geffard, S Lawson-Ayayi, F Dauchy, G Miremont-Salamé, C Greib, S Farbos, P Morlat, F Dabis

Open Access Poster presentation

Long-term follow-up of HIV-infected patients in salvage therapy with raltegravir plus optimized background regimens: a multicentre Italian experience

S Landonio, P Meraviglia, AF Capetti, A Di Biagio, S Lo Caputo, G Sterrantino, A Ammassari, B Menzaghi, M Franzetti, G De Socio, G Pellicanò, E Mazzotta, P Zucchi, G Rizzardini

Open Access Poster presentation

Immunologic impact of maraviroc in clinical practice of a university hospital

S Plata Paniagua, N Trovato Lopez, I Castillo Romera, A Ais Larisgoitia, J Bellon Cano, M Sanjurjo Saez

Open Access Poster presentation

Short-course intensification with enfuvirtide in virologic failure: impact on intracellular HIV reservoir and on viral tropism (INNOVE study)

J Ghosn, C Delaugerre, A Pinta, N Pierre, D Etienne, F Raffi, L Morand-Joubert

Open Access Poster presentation

Efficacy of once daily darunavir/ritonavir 800/100 mg in PI/r-experienced HIV-1 infected patients with suppressed HIV-1 replication: the RADAR study

J Ghosn, A Chermak, A Houssaini, G Peytavin, S Lambert-Niclot, N Eychenne, L Slama, A Brunet, C Duvivier, A Simon, AG Marcelin, P Flandre, C Katlama

Open Access Poster presentation

Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study

E Martínez, JA Arranz, D Podzamczer, M Lonca, J Sanz, P Barragán, H Knobel, E Ribera, F Gutierrez, S Valero, B Clotet, D Dalmau, F Segura, JR Arribas, P Barrufet, I Santos, A Payeras, E de Lazzari, J Pich, J Gatell

Open Access Poster presentation

Tolerance and durability of abacavir/lamivudine (ABC/3TC)-containing regimens: results from a large prospective French cohort

L Cuzin, C Allavena, L Levy-Bachelot, MA Valantin, H Mellliez, P Pugliese, I Poizot-Martin, C Duvivier, L Finkielsztejn, S Abel

Open Access Poster presentation

48-week efficacy and safety of transitioning virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION)

K Arastéh, A Ward, A Plettenberg, JM Livrozet, C Cordes, A Winston, E Wang, A Quinson

Open Access Poster presentation

Lopinavir to atazanavir or darunavir switch in HIV-1-infected patients with dyslipidemia: an observational study

G Le Moal, G Beraud, T Prazuck, L Hocqueloux, A Dupuis, N Venisse

Open Access Poster presentation

Switch to once or twice daily unboosted atazanavir in a cohort of stable HIV patients: strong differences in drug exposure and virological outcome

T Baudry, A Boibieux, MC Gagnieu, L Cotte, JM Livrozet, P Miahles, D Makhloufi, C Chidiac, D Peyramond, T Ferry

Open Access Poster presentation

Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting

S Bonora, A Calcagno, O Viganò, P Bigliano, S Rusconi, L Trentini, MC Tettoni, G Orofino, B Salassa, C Bramato, A D'Avolio, M Siccardi, E Colella, M Galli, G Di Perri

Open Access Poster presentation

Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment-experienced patients (pts) with HIV RNA <50 copies/mL

JL Casado, P Domingo, R Rubio, A Antela, MA Lopez-Ruz, A Castro, J Portilla, E Ribera, D Podzamczer, JA Oteo, J Galindo, S Otero, F Lozano, V Estrada, J Moltó, S Moreno

Open Access Poster presentation

Lopinavir/ritonavir monotherapy in clinical practice

A Caso, E Valencia, V Moreno, M Cervero, J Sanz, R Torres Perea

Open Access Poster presentation

Switching to dual therapy with darunavir/ritonavir and etravirine: a simplification strategy

M Tyrer, L Swaden, NJ Marshall, M Johnson

Open Access Poster presentation

Changes in cerebral function parameters in HIV-1 infected subjects undergoing a treatment simplification to darunavir/ritonavir

LJ Garvey, C Higgs, P Mohammed, M Nelson, A Winston

Open Access Poster presentation

Epidemiological description of the demographic and HIV disease characteristics of HIV patients who are in care but not on treatment in Spain

P Domingo, P Arazo, JL Casado, MA Castaño, E Ferrer, MA Goenaga, R Granados, F Pulido, J Rodriguez, R Rubio, J Sanz, P Viciana

Open Access Poster presentation

Treatment of HIV-2 infection: a retrospective study from a Portuguese center

N Marques, D Seixas, P Crespo, L Malcata, J Vaz, V Mota, C Morais, J Oliveira, V Duque, J Saraiva da Cunha, A Meliço-Silvestre

Open Access Poster presentation

The prognosis of patients with dissociated virological and immunological responses to HAART

DJ Jevtovic, DR Salemovic, JT Ranin

Open Access Poster presentation

Prediction of virological failure in HIV-infected individuals treated with cART in Suriname

MP Bleijenberg, WFW Bierman, C Jaglall, MW Heymans, MC ten Doesschate, PT Nieuwkerk, PH Smits, M van Eer, S Vreden

Open Access Poster presentation

British HIV and ageing study. HIV and ageing: older people with HIV, who are they?

S Allan, RA Daly, Y Yoganathan, S Barrett, A Joseph, A Tariq, CW Saing, C Williams, C Lane, J Sikorska

Open Access Poster presentation

Abstract withdrawn

Open Access Poster presentation

Long-term efficacy and safety of low-dose ritonavir-boosted atazanavir (ATV/r) 200/100 mg in HIV-infected Thai patients

A Avihingsanon, T Apornpong, SJ Kerr, J Ananworanich, K Ruxrungtham

Open Access Poster presentation

Role of platelet activation in the cardiovascular complications associated with HIV infection: differential effect of abacavir versus tenofovir

D Francisci, E Falcinelli, B Belfiori, E Petito, M Mezzasoma, F Baldelli, P Gresele

Open Access Poster presentation

Platelet activity in HIV-infected patients on abacavir-containing antiretroviral therapy

R Palacios, JA González-Correa, J Ruiz, E Nuño, M Márquez, JP de la Cruz, J Santos

Open Access Poster presentation

Cardiovascular risk in patients visiting the Hadassah AIDS Center, Jerusalem

S Schulman, V Rotshild, K Olshtein Pops, M Korem, S Israel, M Hauzi, S Maayan

Open Access Poster presentation

Incidence of ischemic cardiovascular events in the maraviroc clinical development program

S Portsmouth, R Burnside, A Lazzarin, M Johnson, H Valdez

Open Access Poster presentation

Low serum phosphate levels are related to increased cardiovascular risk in HIV-1 infected patients

P Grima, M Guido, R Chiavaroli, P Tundo, A Zizza

Open Access Poster presentation

Prevalence of cardiovascular risk factors in Spanish HIV-1-infected male inmates

JP Golf, L Sala, J Aramburo, P Sardà, N Perez-Alvarez, JM Llibre

Open Access Poster presentation

Nitric oxide protects against HIV gp120 endothelial injury

S Fiorucci, A Mencarelli, D Francisci, E Distrutti, B Renga, F Baldelli

Open Access Poster presentation

Higher red blood cell distribution width is associated with a worse virologic and clinical situation in HIV-infected patients

S Puerta, M Gallego, R Palacios, J Ruiz, E Nuño, M Márquez, J Santos

Open Access Poster presentation

Alexithymia, an impairment of emotional cognitive processing, is a candidate risk factor for carotid artery plaque formation in HIV-infected patients

F Vadini, F Sozio, E Mazzotta, C Agostinone, T Ursini, A Agostinone, G Placido, LM Manzoli, G Parruti

Open Access Poster presentation

Mesenteric fat thickness in a group of HIV patients on HAART

SS Lee, E Liu, KW To

Open Access Poster presentation

Hypertriglyceridemic waist identifies HIV+ men and women at increased cardiometabolic risk

G Guaraldi, S Zona, G Orlando, F Carli, C Stentarelli, J Despres, R Ross

Open Access Poster presentation

Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir

T Overton, JA Aberg, S Gupta, R Ryan, B Baugh, G De La Rosa

Open Access Poster presentation

Adiponectin and leptin levels in HIV-infected patients with lipodystrophy in Southern India

S Mini Jacob, K Annie Phoebe, R Hemalatha, MR Sivakumar, MP Ravindran, MV Natarajan

Open Access Poster presentation

Nutritional status in HIV-infected patients using Changi's mini nutritional assessment

M Cervero, V Alcázar, R Sanz, C García-La Calle, JL Agud

Open Access Poster presentation

Dietician-based approach to lipodystrophic syndrome: role of bioelectrical impedance analysis at week 12

G Orofino, M Guastavigna, P Martinoglio, D Penoncelli, D Demarie, M Tettoni, P Desiderato, R Di Frenna, C Zignin

Open Access Poster presentation

Altered phosphate metabolism in HIV-1-infected patients: another feature of metabolic syndrome?

P Grima, A Zizza, M Guido, P Calabrese, R Chiavaroli, MR Sodo, M Tana, P Tundo

Open Access Poster presentation

Switching to nevirapine (NVP) significantly increases high-density lipoprotein cholesterol (HDL-C) in treatment-experienced patients (NEVICOR study)

JM Rodriguez, M Delgado, P Viciana, MA Lopez-Ruz, M Leal, F Alcacer, E Deig, A Antela, E Pedrol, S Moreno

Open Access Poster presentation

CD4 response, lipid changes and liver outcome in 506 patients receiving nevirapine-based regimens for a median of 9 years

D Podzamczer, JM Tiraboschi, J Mallolas, MA Cárdenes, E Casas, A Castro, S Echevarria, M Leal, JC Lopez Bernanldo de Quirós, S Moreno, T Puig, E Ribera, C Villalonga, JL Gomez Sirvent, JA Garcia Heranejos, J Lopez-Aldeguer, P Barrufet, L Force, I Santos, J Sanz

Open Access Poster presentation

Chronic kidney disease in patients with normal eGFR at baseline: results from EuroSIDA

L Ryom, A Mocroft, P Reiss, B Ledergerber, S De Wit, D Duiculescu, AD Monforte, M Murphy, JD Lundgren, O Kirk

Open Access Poster presentation

Kidney tubular function and serum phosphate levels in HIV-1-infected patients treated with tenofovir: preliminary results

P Grima, A Zizza, P Calabrese, R Chiavaroli, A Faraone, M Tana, MR Sodo, P Tundo, M Guido

Open Access Poster presentation

Smoking, female gender and PI use are associated with decreasing renal function in TDF-containing HAART

A Uglietti, C Gervasoni, E Gabrielli, S Di Giambenedetto, R Cauda, R Esposito, P Grima, G Di Perri, R Maserati, M Galli

Open Access Poster presentation

A magnifying glass onto renal function and serum lipid evolutions after tenofovir (TDF) and emtricitabine (FTC) in combination with atazanavir/ritonavir (ATV/r) versus efavirenz (EFV) as first-line HAART (the INCA trial)

I Izzo, L Albini, A Calabresi, D Motta, R Bellagamba, R Fezza, P Narciso, L Sighinolfi, P Maggi, E Focà, M Mendeni, L Manili, M Magoni, G Carosi, E Quiros-Roldan, C Torti

Open Access Poster presentation

The 10 year safety and efficacy of tenofovir disoproxil fumarate (TDF)-containing once-daily highly active antiretroviral therapy (HAART)

I Cassetti, A Etzel, JV Madruga, JM Suleiman, Y Zhou, M Rhee, DR Warren

Open Access Poster presentation

Intracellular tenofovir-diphosphate accumulation in an HIV-infected patient with Fanconi syndrome and osteomalacia

ME Haverkort, BW van der Spek, PT Lips, WAT Slieker, W Bronsveld

Open Access Poster presentation

The association between metabolic syndrome and the occurrence of nephrolithiasis in HIV-infected patients

IM Dumitru, S Rugina, G Sotila, E Dumitru, CN Rugina

Open Access Poster presentation

Prevalence of chronic renal failure stage 3 or more in HIV-infected patients in Antwerp: an observational study

AW Colson, E Florence, H Augustijn, GA Verpooten, L Lynen, E Gheuens

Open Access Poster presentation

Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients

J Macías, J Mallolas, LF López-Cortés, JA Cartón, P Domingo, S Moreno, JA Iribarren, K Neukam, A Rodrigo, MJ Jiménez-Expósito, JA Pineda

Open Access Poster presentation

Liver fibrosis: concordance analysis between APRI and FIB-4 scores, evolution and predictors in a cohort of HIV patients without HCV and HBV infection

M Mendeni, E Focà, D Gotti, N Ladisa, E Quiros-Roldan, A Vavassori, F Castelnuovo, G Carosi, G Angarano, C Torti

Open Access Poster presentation

Clinical significance of hyperbilirubinemia in the CASTLE study

J Uy, W Hu, V Wirtz, T Hosey, D Butcher, D McGrath, A Farajallah

Open Access Poster presentation

A case of nodular regenerative hyperplasia in a patient who had been taking didanosine

C Jackson, R Fox, M Priest, D Clutterbuck, E Peters

Open Access Poster presentation

Toxic intracellular anabolite levels of tenofovir and didanosine causing a steep CD4-cell decline

E de Jong, ME Haverkort, R ter Heine, RS Jansen, JH Beijnen, MA van Agtmael

Open Access Poster presentation

Lack of association between mitochondrial DNA polymorphisms and didexoxynucleoside-induced hyperlactataemia in black-African, HIV-1-infected patients

A Arenas-Pinto, I Weller, R Ekong, A Grant, A Karstaedt, L Telisinghe, M Bolhaar, S Charalambous, N Bradman, C Ingram

Open Access Poster presentation

Markers of bone turnover are elevated in patients on antiretrovirals independent of the substance used

RJ Piso, M Rothen, JP Rothen, M Stahl

Open Access Poster presentation

Quantitative ultrasound (QUS) in HIV-infected patients: a reliable and low-cost technique for bone health assessment

R Marocco, H Martini, V Belvisi, T Tieghi, R Cesareo, C Del Borgo, M Lichtner, CM Mastroianni

Open Access Poster presentation

Fracture risk in HIV and the need for guidelines: the Probono-1 Trial

B Peters, H Isohanni, S Tillet, F Ibrahim, G Hampson, FMK Williams, MEO Perry, A Duncan, A Wierzbicki

Open Access Poster presentation

Rates of bone fractures in a cohort of HIV-infected adults in the UK

A Samarawickrama, R Malik, M Fisher, Y Gilleece, K Walker-Bone

Open Access Poster presentation

Prevalence of vitamin D deficiency: cross-sectional study of a hospital cohort of HIV-1 infected outpatients

M Cervero, V Alcázar, C García-La Calle, R Sanz, JL Agud

Open Access Poster presentation

Prevalence and factors associated with severe vitamin D deficiency in HIV/hepatitis C co-infected patients

S Surah, A Samarawickrama, L Campbell, R Kulasegaram, F Post, M Fisher, B Peters, J Fox

Open Access Poster presentation

Tenofovir use is associated with low vitamin D levels in a Spanish HIV cohort

M Cervero, C García Lacalle, JL Agud, R Torres Perea, E García-Benaya, J Jusdado, C Pérez Pons, M del Álamo

Open Access Poster presentation

Safety and efficacy of maraviroc (MVC) combined with multiple different therapeutic agents in highly treatment-experienced (TE) patients in Brazil

JJD Furtado, JV Madruga, EL Bicudo, M Eira, MIB Lopes, EM Netto, MS de Oliveira, OHM Leite, AA Machado, U Tupinambas, JL de Andrade Neto, MPJ Lima, DB Wajsbrot, LM Cassoli

Open Access Poster presentation

Behaviour and attitudes in HIV (BEAHIV): a national survey study to examine the level of agreement between physicians and patients in symptom reporting

A Rachlis, J Gill, M Harris, J Macleod, C Worthington, J Brunetta, A Tsang, H Hew, J Leith, F Camacho, D Turner, C Fraser

Open Access Poster presentation

Continuing burden of HIV late presenters in the North East of England 2009

N Premchand, K Golds, PY Tan, I Bittiner, N Sanker, ELC Ong

Open Access Poster presentation

Drug interactions in the elderly HIV-infected patient

C Coroiu, F Tollinchi, G Hittinger, S Mokhtari, P Granet, O Faucher-Zaegel, A Madrid, A Menard, JL Mattei, S Chadapaud

Open Access Poster presentation

Sexual dysfunction and anxiety in HIV-1-infected males in Eastern Sicily

BM Celesia, C Coco, F Bisicchia, G Pellicanò, MT Mughini, F Palermo, G Nunnari, R Russo

Open Access Poster presentation

Raltegravir-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: implications for clinical practice and patient safety

MEO Perry, N Almaani, N Desai, J Fox, N Larbalestier, D Chilton

Open Access Poster presentation

Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from a multicenter study

G Madeddu, V Soddu, E Ricci, T Quirino, B Menzaghi, C Bellacosa, C Grosso, S Melzi, L Valsecchi, M Franzetti, F Vichi, G Penco, A Di Biagbio, G Pellicanò, L Corsico, GVL De Socio, E Mazzotta, G Parruti, M Guastavigna, G Orofino, MS Mura, P Bonfanti

Open Access Poster presentation

Efavirenz use and contraceptive methods in HIV-positive women in a large urban cohort

RA Seaton, R Fox, A MacConnachie, P Anderson, R Nandwani, E Peters, A Winter, R Taylor

Open Access Poster presentation

Assessing the risk of birth defects associated with atazanavir exposure in pregnancy

S Esker, J Albano, H Tilson, J Uy, D Arikan, K Krantz, MJ Jiménez-Expósito, D Seekins

Open Access Poster presentation

Administration of darunavir tablets in patients with difficulties in swallowing – two case reports

S Scholten, S Mauruschat, S Hindermann, B Ranneberg

Open Access Poster presentation

Adherence, quality of life and number of daily pills in a large cross-sectional study

N Gianotti, L Galli, B Bocchiola, T Cahua, P Panzini, D Zandonà, S Salpietro, M Maillard, A Danise, A Pazzi, A Lazzarin, A Castagna

Open Access Poster presentation

Changing HIV guidelines: how to communicate treatment start

J Fehr, D Nicca, W Langewitz, D Haerry, M Battegay

Open Access Poster presentation

Relating protease inhibitor resistance at time of virological failure with drug exposure

M Van Luin, WP Bannister, R Paredes, AN Phillips, J Bruun, J Van Lunzen, O Kirk, A d'Arminio Monforte, A Cozzi-Lepri, DM Burger

Open Access Poster presentation

Does feedback of medication execution using MEMS caps aid adherence to HAART?: the MEMRI study (MEMS as Realistic Intervention)

S Davies, S Asghar, V Cooper, A Lange, C Robertson, B Vrijens, DJ White

Open Access Poster presentation

Antiretroviral regimen complexity as a predictor of adherence

C Boyle, A Wilson, G Treacy, G Sheehan, J Lambert, C Meegan, P Mallon

Open Access Poster presentation

Naïve patients receiving TDF/FTC-EFV as 2 pills are more likely to modify regimen components than patients receiving a TDF/FTC/EFV single pill

I Perez-Valero, N Martin, B Jose Jose Valiente, JI Bernardino-Serna, M Mora, F Gaya, J Gonzalez, FX Zamora, JM Pena, JR Arribas

Open Access Poster presentation

Identifying causes of loss to follow up in newly diagnosed HIV-infected patients

V Fridman, NS Bello, MB Lasala

Open Access Poster presentation

Transmitted drug resistance associated with transmission clusters in newly diagnosed antiretroviral-naïve patients in Northern Greece

L Skoura, S Metallidis, AJ Buckton, JL Mbisa, D Pilalas, E Papadimitriou, A Papoutsi, AB Haidich, D Valagouti, O Tsachouridou, ZA Antoniadou, P Kollaras, P Nikolaidis, N Malisiovas

Open Access Poster presentation

Detection of HIV type 1 mutations on the pol region in untreated patients in Northern Vietnam: determination of drug resistance and subtypes

S Ranger-Rogez, M Al Jawhari, B Nguyen, N Pham Hong, T Tran Quoc, J Pascual, J Doll, M Harzic, G Viretto, P Weinbreck

Open Access Poster presentation

Population and ultra-deep sequencing for tropism determination are correlated with Trofile ES: genotypic re-analysis of the A4001078 maraviroc study

S Portsmouth, S Valluri, M Daeumer, B Thiele, H Valdez, M Lewis, C Craig, A Thielen, I James, J Demarest, J Heera

Open Access Poster presentation

Clinical application of genotypic co-receptor tropism testing from viral RNA and proviral DNA: week 24 analysis of the Berlin maraviroc cohort

MJ Obermeier, A Carganico, S Dupke, D Schranz, C Cordes, M Freiwald, G Klausen, S Köppe, C Schuler, C Mayr, D Schleehauf, T Berg, I Krznaric, A Baumgarten

Open Access Poster presentation

Analysis of BENCHMRK 1 & 2 using PhenoSense® assay for darunavir (DRV/r) resistance and exploration of functional monotherapy with RAL vs DRV

J Rockstroh, J Eron, D Cooper, R Steigbigel, BY Nguyen, X Xu, H Wan, A Rodgers, M Miller, R Leavitt, P Sklar, H Teppler

Open Access Poster presentation

Analysis of major and minor IAS-USA PI mutations in the MONET trial of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs

F Pulido, JR Arribas, A Hill, Y van Delft, C Moecklinghoff

Open Access Poster presentation

Changing prevalence of darunavir resistance-associated mutations (DRV RAMs) in clinical samples received for routine resistance testing: 2003-2009

G De La Rosa, T Pattery, G Picchio, E Lathouwers, J Villacian, K Van der Borght

Open Access Poster presentation

Darunavir resistance spectrum in darunavir-na#239;ve patients harboring virological failure to antiretroviral therapy

AG Marcelin, C Charpentier, M Wirden, D Descamps, V Calvez

Open Access Poster presentation

Resistance after viral failure on atazanavir-containing therapy: multinational clinical cohort (BMS AI424-128 — 'IMPACT') final analysis

A Zolopa, W Towner, A Lazzarin, G Fätkenheuer, D Butcher, J Uy

Open Access Poster presentation

High levels of polymorphisms related to raltegravir resistance among raltegravir-naïve individuals in Brazil

N Mantovani Pena, R Gonçalves Azevedo, D Funayama Castro, R Sobhie Diaz, S Vasconcelos Komninakis

Open Access Poster presentation

Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens

AG Marcelin, C Charpentier, C Ferreira, M Wirden, C Lemarchand, D Descamps, V Calvez

Open Access Poster presentation

Abstract withdrawn

Open Access Poster presentation

Is extended resistance to the historical antiretroviral drugs & drug classes still a risk factor for HIV progression?

M Zaccarelli, P Lorenzini, P Marconi, F Forbici, C Gori, P Sette, F Ceccherini-Silberstein, P Narciso, CF Perno, A Antinori

Open Access Poster presentation

Prevalence of HIV drug-resistance mutations in HIV-infected Mexican patients heavily experienced to antiretroviral therapy

JE Gaytán-Martínez, JA Mata-Marín, F Gutierrez-Escolano, L Pérez-Saleme, S Treviño-Pérez, JG Vázquez-Rosales, N Matías-Juan, RD Díaz-Ramos, R Arias-Flores

Open Access Poster presentation

HIV drug resistance in children with treatment failure to first-line regimens in Ho Chi Minh City, Vietnam

VTT Nhung, D Colby, TH Khanh, TT Viet, D Lu, HT Thuy, B An, LT Giang

Open Access Poster presentation

Molecular epidemiology of antiretroviral resistance in therapy-experienced HIV-1 patients in Cuba (2009)

L Pérez, J Aleman, C Correa, J Pérez, C Fonseca, C Aragones, D Pérez, A Alvarez, AM Vandamme, V Kourí, K Van Laethem

Open Access Poster presentation

Development of drug resistance among HIV-1 F1 sub-type patients with treatment failure

A Temereanca, CM Sultana, L Manolescu, C Vagu, C Grancea, S Ruta

Open Access Poster presentation

Pro-viral DNA and antiretroviral treatment simplification

D Zucman, C Rouzioux, V Avettand-Fenoel

Open Access Poster presentation

Haemoglobin and anaemia in the SMART study

A Mocroft, AR Lifson, G Touloumi, J Neuhaus, Z Fox, A Palfreeman, M Vjecha, S Hodder, S De Wit, JD Lundgren, AN Phillips

Open Access Poster presentation

Genotype testing in HIV-infected pregnant women

C Afonso, A Zagalo, N Janeiro, F Antunes

Open Access Poster presentation

High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece

P Panagopoulos, D Paraskevis, V Sypsa, M Detsika, K Protopapas, V Sakka, G Poulakou, A Papadopoulos, G Petrikkos, A Hatzakis

Open Access Poster presentation

Feasibility of testing antibodies to HIV from filter paper using HIV rapid test kits

A Ganesan, G Thatchinamoorthy, S Saramini

Open Access Poster presentation

Effect of lipemia and bilirubinemia on HIV-1 protease and reverse transcriptase genotyping and phenotyping success: a five-year analysis

T Pattery, A Van Cauwenberge, M Van Hove, V Smits, K Van Soom, J Villacian

Open Access Poster presentation

Lack of utility of phosphate serum monitoring in HIV-infected patients on a tenofovir-based antiretroviral regimen

P Wikman, P Safont, MJ Perez-Elías, A Moreno, F Dronda, S Moreno, JL Casado

Open Access Poster presentation

CCR5 D32 modifies 15-year mortality risk associated with well-established clinical and immunological factors among HIV-infected patients

M Parczewski, M Leszczyszyn-Pynka, D Bander, A Urbañska, M Kaczmarczyk, S Ciechanowicz, A Boron-Kaczmarska

Open Access Poster presentation

What drives a normal relation between T-CD4 and T-CD8?

R Badura, RJG Antunes, N Janeiro, C Afonso, F Antunes

Open Access Poster presentation

Comparative evaluation of ARV therapy efficiency among patients at the Kiev regional AIDS center

YO Yurchenko, T Stepchenkova, KI Karnets, MO Martinenko

Open Access Poster presentation

Salvage therapy with raltegravir in a 3-month-old infant

AB Brolund, C Ilchmann, R Ganschow, O Degen

Open Access Poster presentation

High preterm delivery rates associated with initiation of HAART during pregnancy

GP Taylor, M Douglas, J Smith

Open Access Poster presentation

Minority M184V variants in women exposed to 3TC/FTC-containing lopinavir-ritonavir (LPVr) regimens in pregnancy

S Surah, S Oshea, S Costelloe, M Hanlon, J Mullen, I Chrystie, GP Taylor, A De Ruiter

Open Access Poster presentation

Antiretroviral strategies for the treatment of pregnant HIV+ women and prevention of perinatal HIV transmission in Dodoma, Tanzania: AMANI Study

G Liuzzi, F Vairo, Z Chaula, B Nguhuni, E Nicastri, N Bevilacqua, A Cannas, MG Paglia, G Ippolito

Open Access Poster presentation

Use of antiretroviral therapy during pregnancy among HIV-infected women attending an urban care centre

F Ssewankambo, C Nalugwa, J Sempa, J Walusimbi, A Kambugu

Open Access Poster presentation

A complex of measures effectiveness in reducing mother-to-child HIV transmission

SV Minaeva, GF Moshkovich

Open Access Poster presentation

Amniocentesis is a low-risk procedure in HIV-treated pregnant women

MM Simoes, CO Marques, F Albergaria, C Guerreiro, A Pereira, J Correia, J Castela

Open Access Poster presentation

Pregnancy decisions and contraceptive use among HIV-positive women: a study in a large urban clinic in sub-Saharan Africa

J Walusimbi, E Birabwa, E Nabankema, A AnneMarie, I Lutalo, A Nakiwooga

Open Access Poster presentation

BEST: Better Equipped to Start Treatment

J Bennett

Open Access Poster presentation

Older HIV-infected individuals present late and have a higher mortality: a UK clinic cohort study

CC Iwuji, D Pao, Y Gilleece, M Fisher, D Churchill

Open Access Poster presentation

Offering HIV testing in an emergency admission unit in Newcastle upon Tyne, UK — a pilot audit study

S Ellis, L Graham, DA Price, ELC Ong

Open Access Poster presentation

A high occurrence of late presenters and missed HIV diagnosis in clinical care in Sweden

J Brännström, V Svedhem, A Yilmaz, A Blaxhult, S Wendahl, A Sönnerborg

Open Access Poster presentation

Audit of telephone HIV clinics: effective and acceptable

WFC Woolley, C Babu, A Sukthankar, O McQuillan

Open Access Poster presentation

Adherence to HIV treatment guidelines for initiation of antiretroviral therapy in Australia

M Bloch, J Hoy, N Cunningham, N Roth, N Andrianopoulos, C Rayner, A Carr

Open Access Poster presentation

Five-year outcomes of HAART at a non-governmental treatment center in Lima, Peru

N Castillo, C Agurto, C Benites, JA Hidalgo

Open Access Poster presentation

The impact of late presentation: analysis of a cohort of 313 Portuguese patients

D Alfaiate, AC Miranda, J Rijo, D Fernandes, F Borges, H Farinha, K Mansinho

Open Access Poster presentation

T-CD4+ cell count at the date of the HIV diagnosis

AR Domingues da Silva, J Mendez, R Sarmento e Castro

Open Access Poster presentation

Pharmacokinetics of lamivudine, abacavir and zidovudine administered twice daily as syrups versus scored tablets in HIV-1-infected Ugandan children

PK Gitta, L Kendall, V Musiime, K Adkison, AA Kekitiinwa, A Ferrier, O Opilo, Y Lou, MF Bwakura-Dangarembi, P Nahirya-Ntege, S Bakeera-Kitaka, M Ssenyonga, W Snowden, D Burger, AS Walker, D Gibb

Open Access Poster presentation

Therapeutic drug monitoring (TDM) of atazanavir in pregnancy

LJ Else, V Jackson, M Brennan, J Breiden, C Weldridge, S Coulter-Smith, DJ Back, SH Khoo, J Lambert

Open Access Poster presentation

SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV-infected patients

M Siccardi, A D'Avolio, L Baietto, M Simiele, S Bonora, DJ Back, G Di Perri, A Owen

Open Access Poster presentation

A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load

A Calcagno, MG Milia, A D'Avolio, P Ndayishimiyae, P Dusabimana, S Bonora, J Cusato, M Simiele, R Rostagno, M Siccardi, S Audagnotto, V Ghisetti, G Di Perri

Open Access Poster presentation

Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100, 200/150, and 200/50 mg twice daily in HIV-negative volunteers

AGA Jackson, A Hill, LJ Else, DJ Back, R Morley, R Puls, J Amin, E Lin, M Boffito

Open Access Poster presentation

Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi

L Dickinson, M Chaponda, D Carr, JJ van Oosterhout, J Kumwenda, DG Lalloo, M Pirmohamed, R Heyderman, SH Khoo

Open Access Poster presentation

PK/PD modeling supports the dose-escalation decision in VIKING

M Lovern, M Underwood, G Nichols, I Song

Open Access Poster presentation

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients

L Dickinson, AGA Jackson, LJ Garvey, V Watson, SH Khoo, A Winston, M Boffito, GR Davies, DJ Back

Open Access Poster presentation

Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial

V Sekar, G De La Rosa, T Van de Casteele, S Spinosa-Guzman, P Vis, RMW Hoetelmans

Open Access Poster presentation

Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-naïve, HIV-1-infected patients in ECHO and THRIVE

HM Crauwels, E van Schaick, RPG van Heeswijk, S Vanveggel, K Boven, P Vis

Open Access Poster presentation

Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients

J Moltó, M Valle, C Miranda, S Cedeño, E Negredo, MJ Barbanoj, B Clotet

Open Access Poster presentation

Moringa oleifera supplementation by patients on antiretroviral therapy

TG Monera, CC Maponga

Open Access Poster presentation

The use of a darunavir/ritonavir once-daily regimen in two pregnant women

JS Lambert, LJ Else, V Jackson, L Dickinson, DJ Back, M Brennan, C Weldridge, S Coulter-Smith, S Gibbons, SH Khoo

Open Access Poster presentation

Treatment of chronic invasive fungal sinusitis with voriconazole in an HIV patient

A Ho, G McGarry, E Peters

Open Access Poster presentation

Opportunistic infections (OIs) present in HIV-seropositive patients: a study

K Ayodhya Ramaiah, B Sudha Rani, R Anand, S Ramola, P Satish Babu, R Ramesh Babu

Open Access Poster presentation

Immunological diagnosis of CMV infection in HIV-infected patients

IM Dumitru, S Rugina, E Dumitru, RC Cernat, S Diaconu, C Maxim Mitroi

Open Access Poster presentation

Epidemiology of HIV-associated tuberculosis (TB) co-infection in Krasnoyarsk region, Russian Federation

TA Chaychuk, NU Gankina, OG Nikonova

Open Access Poster presentation

A minority of tuberculosis cases occurring during HIV care is possibly preventable

L Skeie, T Skrede, A Maeland

Open Access Poster presentation

Generalized tuberculosis in HIV-infected patients with AIDS

VN Zimina, IA Vasilieva, AV Kravchenko, FA Batyrov

Open Access Poster presentation

Therapy of the patients with HIV/TB infection and dynamics of level 'naïve' CD4-lymphocytes

AA Popova, AV Kravchenko, GM Kozhevnikova, LV Serebrovskaya

Open Access Poster presentation

Enfuvirtide in therapy at patients with HIV-infection and tuberculosis

AV Kravchenko, AV Kuznetsova, OA Kozyrev, VA Lukyanova, VG Kanestri

Open Access Poster presentation

Sudden unexplained death in a patient with HIV and MDR-TB

E Boxall, J Milne, E Peters, C Sykes

Open Access Poster presentation

Hepatitis C virus (HCV) infection and re-infection among HCV- and HIV/HCV-infected injection drug users

B Conway, A Barrieshee, HK Tossonian, K Wight, S Jassemi, M Tong, E Knight, L Gallagher, F Duncan, S DeVlaming

Open Access Poster presentation

Increasing numbers of acute hepatitis C infections in HIV-infected MSM and high reinfection rates following SVR

HJ Stellbrink, CK Schewe, M Vogel, C Noah

Open Access Poster presentation

High prevalence of genotype G in HIV co-infected patients compared with HBV monoinfected patients in México

JA Mata-Marín, JE Gaytán-Martínez, CI Arroyo-Anduiza, G Calderón-Rodriguez

Open Access Poster presentation

Acute hepatitis C in persons infected with the human immunodeficiency virus (HIV): the 'real-life setting' proves the concept

P Ingiliz, MJ Obermeier, L Weitner, C Cordes, A Moll, B Hintsche, F Schlote, S Köppe, C Mayr, A Baumgarten

Open Access Poster presentation

Correlates of hepatic stiffness by FibroScan© in a multicentric Italian cohort of HIV-infected patients

P Tarquini, F Sozio, E Marchionni, E Gabrielli, E Polilli, F Ancarani, D Di Giammartino, LM Manzoli, G Parruti

Open Access Poster presentation

Role of HCV infection in the development of carotid atherosclerosis in a cohort of HIV-infected patients

S Ferrara, A Tartaglia, T Santantonio, B Grisorio

Open Access Poster presentation

Do interleukin-28B single nucleotide polymorphisms influence the natural history of chronic hepatitis B?

L Martín-Carbonero, NI Rallón, JM Benito, E Poveda, J González-Lahoz, V Soriano

Open Access Poster presentation

No impact of IL28B polymorphisms on liver enzymes in patients coinfected with HIV and HCV

JV Fernández-Montero, L Martín-Carbonero, P Barreiro, NI Rallón, JM Benito, J González-Lahoz, V Soriano

Open Access Poster presentation

Effectiveness of pegylated interferon alfa plus HAART in HIV/HBV treatment-naïve coinfected patients

JA Mata-Marín, CI Arroyo-Anduiza, R Arias-Flores, JE Gaytán-Martínez

Open Access Poster presentation

Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy

P Labarga, ME Vispo, JM Guardiola, C Miralles, L Martín-Carbonero, J Portu, P Barreiro, P Miralles, J Morello, MJ Tellez, P Bancalero, V Asensi, NI Rallón, I Santos, L Morano, K Aguirrebengoa, MJ Rios, R Rubio, K Neukam, J González-Lahoz, V Soriano

Open Access Poster presentation

Efficacy and safety of therapy of chronic hepatitis B with telbivudine (LdT) in patients with HIV-infection without HAART

SP Tsarenko, AV Kravchenko, VG Kanestri, SL Maximov

Open Access Poster presentation

Efficacy and safety of TMC278 in treatment-naïve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the phase III ECHO and THRIVE trials

M Nelson, G Amaya, N Clumeck, C Arns Da Cunha, D Jayaweera, P Junod, L Taisheng, P Tebas, M Stevens, A Buelens, S Vanveggel, K Boven

Open Access Poster presentation

Efficiency of HIV-1 PR-RT genotyping is not impacted by co-infection with HCV

ACA Deloof, H De Wolf, Y Verlinden, J Villacian, T Pattery

Open Access Poster presentation

Relationship between dynamics of Epstein-Barr virus and immune activation in HIV-1 infected subjects in the HAART era

AM Cattelan, M Zanchetta, L Sasset, R Petrara, R Freguja, K Gianesin, MG Cecchetto, F Cremona, A De Rossi

Open Access Poster presentation

Abstract withdrawn

Open Access Poster presentation

Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastin in HIV-infected patients with Hodgkin lymphoma

A Cingolani, L Torti, C Pinnetti, K de Gaetano Donatil, R Murri, E Tacconelli, LM Larocca, L Teofili

Open Access Poster presentation

Cancer chemotherapy: early experience with combined chemotherapy for HIV-infected Kaposi's sarcoma patients at Lighthouse clinic, Lilongwe, Malawi

HF Mulinde, H Tweya, J Chiwoko, C Feldacker, S Phiri, M Nyirenda, R Weigel, L Mlundira

Open Access Poster presentation

HIV testing in non-traditional settings: feasibility and acceptability in an acute admissions unit

R Cridford, A Thornton, M Rayment, S Mguni, D Millett, S Mandalia, A Nardone, M Tenant-Flowers, A Sullivan, R Ghosh, J Anderson

Open Access Poster presentation

Clinical profile of HIV/AIDS patients admitted to a tertiary outpatient clinic in Istanbul, Turkey

O Aydin Altuntas, H Kumbasar Karaosmanoglu, R Korkusuz, O Nazlican

Open Access Poster presentation

Causes of death in patients infected with HIV from 1985 to 2008

J Mendez, R Sarmento e Castro, AR Domingues da Silva

Open Access Poster presentation

Syphilis infection is associated with an increase in plasma viral load in HIV infected patients: results from the FHDH cohort — ANRS CO4

W Jarzebowski, C Piketty, P de Truchis, E Caumes, D Farhi, AS Lascaux, MA Bouldouyre, O Derradji, J Pacanowski, N Dupin, D Costagliola, S Grabar

Open Access Poster presentation

Low immunogenicity of whole virion, verocell-derived, inactivated, pandemic influenza H1N1 vaccine in HIV-infected patients

H Lagler, K Grabmeier-Pfistershammer, V Touzeau-Römer, S Tobudic, A Rieger, H Burgmann

Open Access Poster presentation

No effect of a single supratherapeutic dose of lersivirine, a next-generation NNRTI, on QTc interval in healthy subjects

M Vourvahis, R Wong, NM Ndongo, M O'Gorman, M Tawadrous

Open Access Poster presentation

Leukocyte extract reduces HIV replication and modulates cellular factors involved in HIV infection: therapeutic meant

C Fernandez-Ortega, D Casillas, M Dubed, L Navea, A Ramirez, L Lopez, T Paneque, Y Reinoso

Open Access Poster presentation

Novel monitoring technique to minimise the risk for patients participating in pilot studies of investigational compounds

R Cuffe, M Ait-Khaled, S Hughes, S Min, G Nichols, D Thomas, M Underwood, JM Yeo

Open Access Poster presentation

Abstract withdrawn

Open Access Poster presentation

Prevalence of type 2 diabetes mellitus and its predictive factors in Italy: a comparison between HIV-infected and uninfected subjects

L Galli, S Salpietro, G Pellicciotta, A Galliani, PM Piatti, H Hasson, M Guffanti, N Gianotti, A Bigoloni, A Lazzarin, A Castagna

Open Access Poster presentation

Smoking prevalence, cessation rates and relapse rates in the Swiss HIV Cohort Study (SHCS)

M Huber, B Ledergerber, R Jaccard, L Elzi, H Furrer, B Hirschel, M Cavassini, E Bernasconi, P Schmid, R Weber

Open Access Poster presentation

Prevalence and risk factors for chronic obstructive lung disease in HIV-infected patients in the HAART era

G Madeddu, AG Fois, GM Calia, F Becciu, B Piras, ML Fiori, V Spada, C Lovigu, M Mannazzu, P Pirina, MS Mura

Open Access Poster presentation

High plasma levels of parathyroid hormone (PTH) are associated with an increased cardiovascular risk among HIV-infected subjects

V Spagnuolo, L Galli, S Salpietro, C Vinci, F Cossarini, G Travi, A Rubinacci, G Mignogna, M Cernuschi, S Bossolasco, A Lazzarin, A Castagna

Open Access Poster presentation

Cost-efficacy analysis of the MONET trial using Spanish antiretroviral drug prices

JR Arribas, A Hill, I Garcia, A Anceau

Open Access Poster presentation

Late versus non-late presentation of HIV/AIDS: an economic impact analysis

K Grabmeier-Pfistershammer, A Rieger, T Schroeck, M Schlag

Open Access Poster presentation

Cost-effectiveness of 2NRTI+NNRTI versus 2NRTI+PI as the initial cART regimen

F Aragão, I Vaz Pinto, J Vera

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.